An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb5871 on Disease Activity in Patients With IgG4-Related Disease.

Trial Profile

An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb5871 on Disease Activity in Patients With IgG4-Related Disease.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2017

At a glance

  • Drugs XmAb 5871 (Primary)
  • Indications Immunological disorders
  • Focus Therapeutic Use
  • Sponsors Xencor
  • Most Recent Events

    • 04 Nov 2017 According to a Xencor media release, primary endpoint has been met. (Proportion of patients with an improvement in IgG4-RD activity).
    • 04 Nov 2017 Results presented in a Xencor Media Release.
    • 04 Nov 2017 According to a Xencor media release, data were presented at the American College of Rheumatology (ACR) 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top